Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.
|Original language||English (US)|
|Title of host publication||Anticancer Treatments and Cardiotoxicity|
|Subtitle of host publication||Mechanisms, Diagnostic and Therapeutic Interventions|
|Number of pages||8|
|Publication status||Published - Jan 1 2017|
ASJC Scopus subject areas